Figure 6. Combination of roniciclib and sorafenib therapy in a murine MTC xenograft tumor model.

(A) TT flank tumors were established in nude mice and treated with oral gavage of placebo, roniciclib (1.4 mg/kg), sorafenib (25 mg/kg) and combination therapy once a day for three cycles of 4-day on and 3-day off therapy. Tumor growth was significantly lower for mice treated with combination therapy compared with single modality treatment or control on day 17 and day 20. (B) No significant changes in body weight attributable to therapy with roniciclib, sorafenib, or combination therapy were observed compared with the placebo group. Arrow, placebo, roniciclib, sorafenib and combination treatment.